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enhances the practice of optometry than 
60 units covering management. Conran 
also called the Board's treatment of for-
eign-trained graduates a disgrace, al-
luding to the Board's past refusal to 
accept foreign optometric training, and 
its foot-dragging in creating a remedial 
training course for foreign graduates 
after being directed to do so by the 
legislature. (See CRLR Vol. 10, Nos. 2 
& 3 (Spring/Summer 1990) p. 113; Vol. 
9, No. 4 (Fall 1989) p. 73; and Vol. 9, 
No. 3 (Summer 1989) pp. 64-65 for 
extensive background information.) 
Conran concluded his remarks by 
offering his assistance and encouraging 
the Board to make constructive changes 
before DCA or the legislature imposes 
changes on the Board without regard to 
its input. "You'd better get with it 
quickly," observed Conran. Board mem-
bers had no questions for Conran. 
At its November meeting, the Board 
elected the following officers for 1992: 
Thomas R. Nagy, president; Pamela J. 
Miller. vice president; and Julia Preisig, 
secretary. Nagy and Miller are optom-
etrists and Preisig is a public member 
of the Board. Also, Bob Miller has been 
reassigned to the Board to replace Steve 
Martini as the Board's DCA legal 
advisor. 
FUTURE MEETINGS: 
May 29-30 (location undecided). 
BOARD OF PHARMACY 
E.rerntil'e Officer: Patricia Harris 
(9/6) 445-50/4 
Pursuant to Business and Professions 
Code section 4000 et seq., the Board of 
Pharmacy grants licenses and permits 
to pharmacists, pharmacies, drug manu-
facturers, wholesalers and sellers of hy-
podermic needles. It regulates all sales 
of dangerous drugs, controlled sub-
stances and poisons. The Board is au-
thorized to adopt regulations, which are 
codified in Division 17, Title 16 of the 
California Code of Regulations (CCR). 
To enforce its regulations, the Board 
employs full-time inspectors who in-
vestigate accusations and complaints 
received by the Board. Investigations 
may be conducted openly or covertly as 
the situation demands. 
The Board conducts fact-finding and 
disciplinary hearings and is authorized 
by law to suspend or revoke licenses or 
permits for a variety of reasons, includ-
ing professional misconduct and any 
acts substantially related to the practice 
of pharmacy. 
The Board consists of ten members, 
three of whom are public. The remain-
ing members are pharmacists, five of 
whom must be active practitioners. All 
are appointed for four-year terms. 
MAJOR PROJECTS: 
Pharmacy Technician Regulations. 
AB I 244 (Polanco) (Chapter 841, Stat-
utes of 1991 ), which was signed into 
law on October 11, permits a pharmacy 
technician, as defined, to perform pack-
aging, manipulative, repetitive, or other 
nondiscretionary tasks while assisting, 
and while under the direct supervision 
of, a registered pharmacist. (See CRLR 
Vol. 11, No. 4 (Fall 1991) pp. 105-06 
for background information.) The Board 
of Pharmacy is authorized to adopt regu-
lations defining the functions which may 
be performed by a pharmacy techni-
cian. In December, the Board published 
notice of its intent to amend section 
1717 ( c) and adopt new sections 1793-
1793. 7, Division 17, Title 16oftheCCR, 
to define the qualifications and permis-
sible duties of pharmacy technicians. 
Existing section I 7 I 7(c) lists certain 
duties which must be performed by a 
pharmacist and those duties which may 
be performed by non-licensed person-
nel, such as typing prescription labels 
and requesting and receiving refill au-
thorization subject to prior review by a 
pharmacist. The Board proposes to in-
corporate portions of this section into 
new sections 1793.1 and 1793.3. Spe-
cifically, proposed section 1793.1 would 
list functions which only a pharmacist 
may perform and which may not be 
delegated to a pharmacy technician; sec-
tion 1793.2 would identify the tasks 
which a pharmacy technician may per-
form under the direct supervision and 
control of a licensed pharmacist, in-
cluding removing drugs from stock, 
counting, pouring, or mixing pharma-
ceuticals. placing the products into a 
container, affixing labels to containers, 
packaging and repackaging; and pro-
posed section 1793.3 would describe 
and update tasks which may be per-
formed by non-licensed personnel who 
are not pharmacy technicians, to include 
the entry of prescriptions into a com-
puter record system. 
Proposed section 1793.4 would es-
tablish registration requirements for 
pharmacy technicians, and authorize the 
Board to issue a certificate to an appli-
cant who has met any of the following 
requirements: has obtained at least an 
associate of arts degree in a field of 
study directly related to the duties per-
formed by a pharmacy technician; has 
completed a training course specified 
by the Board; is eligible to take the 
Board's pharmacist licensure exam; or 
has one year's experience (a minimum 
of 1,500 hours) performing the tasks of 
a pharmacy technician while assisting a 
pharmacist in the preparation of pre-
scriptions in specified facilities. Sec-
tion 1793.5 would specify the training 
courses which are acceptable to the 
Board in satisfaction of the requirement 
in section 1793.4. Section 1793.6 would 
establish requirements for pharmacies 
employing technicians; in particular, it 
clarifies that nonpharmacist personnel 
must work under the direct supervision 
of a registered pharmacist, the supervis-
ing pharmacist must be on the premises 
at all times, and the pharmacist must 
indicate that all prescriptions prepared 
by a technician have been checked by 
initialing the prescription label before 
the medication is given to the patient. 
The subsection also requires a techni-
cian to wear identification clearly iden-
tifying him/her as a technician. 
The Board held an informational pub-
lic hearing on the proposed pharmacy 
technician regulations on November 12; 
it was scheduled to hold a formal regu-
latory hearing on these regulations on 
January 21. 
Locked Storage and Emergency 
Delivery Requirements for Medical 
Device Retailers. Since July 1991, the 
Board of Pharmacy has licensed medi-
cal device retailers (MDRs) as a sepa-
rate class. MDRs are non-pharmacy 
firms that may dispense, upon prescrip-
tion, "dangerous devices" such as hy-
podermic syringes and other items that 
are marked by the manufacturer as avail-
able upon prescription only. Each retail 
site of an MOR must have a Board-
licensed individual designated as "in 
charge." This individual may be a phar-
macist or an "exemptee," a separately-
licensed individual authorized to dis-
pense dangerous devices. The Board 
recently proposed the adoption of new 
sections 1748.1 and 1748.2, Title 16 of 
the CCR, regarding the proper storage 
of dangerous devices at MOR retail sites 
and the delivery of devices to patients 
after hours or in emergency situations. 
Proposed section 1748.1 would pro-
vide that an MOR may use locked stor-
age (a lock box or locked area) for the 
emergency dispensing of dangerous de-
vices. Locked storage may be installed 
or placed in a service vehicle of the 
MOR for purposes of delivery, set-up, 
or after-hours emergency service of dan-
gerous devices to patients having pre-
scriptions on file for the dangerous de-
vice. No hypodermic needles or syringes 
may be stored in this locked storage. 
Section 1748.1 would also provide that 
dangerous devices shall be furnished 
from the locked storage only upon the 
oral or written authorization of an 
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exemptee to an employee of the MOR 
who operates the service vehicle; the 
service vehicle and the locked storage 
contained therein shall be locked at all 
times: a current inventory and record of 
all dangerous devices placed into and 
furnished from the locked storage shall 
be maintained by the MOR for three 
years; within 72 hours of furnishing a 
dangerous device from the emergency 
storage, the exemptee shall be respon-
sible for checking the contents of the 
locked storage and noting the danger-
ous devices furnished on the inventory; 
and the exemptee shall be responsible 
for checking the contents of the locked 
storage on a weekly basis. 
Proposed section 1748.2 would per-
mit an MOR to keep a dangerous device 
in a retail area of the premises during 
the absence of an exemptee. if the de-
vice is of sufficient size and weight as 
to make removal "difficult." The Board 
was scheduled to conduct a public hear-
ing on this proposal on January 22. 
Board Delays Patient Consultation 
Regulations Again. In August 1990, the 
Office of Administrative Law (OAL) 
approved the Board's adoption of new 
sections 1707. I and 1707 .2. Title 16 of 
the CCR, which require pharmacists to 
maintain patient medication profiles for 
all ongoing patient-consumers and pro-
vide an oral consultation to each patient 
or patient's agent, with specified excep-
tions. The oral consultation requirement 
was originally scheduled to take effect 
on March I, 1991. However, on Janu-
ary 11, 1991, OAL approved the Board's 
request to delay the effective date until 
January I, 1992. (See CRLR Vol. IL 
No. 2 (Spring 1991) p. 98 for back-
ground information.) The Board delayed 
the implementation to (I) provide phar-
macists with additional time to prepare 
for and phase in the changes to phar-
macy practice mandated by sections 
1707.1 and 1707.2; (2) permit a more 
assistive resolution to the pharmacy 
technician issue; and (3) amend Board 
regulations to foster spatial arrange-
ments in pharmacies that are conducive 
to privacy for performing patient con-
sultation. However, at this writing, the 
Board has not yet proposed regulations 
concerning spatial arrangements. and 
only recently initiated its proceeding to 
adopt technician regulations (see supra). 
At its October 16 meeting, the Board 
heard a report from its Patient Consul-
tation Implementation Committee, 
which was formed to hear concerns from 
and provide feedback to interested par-
ties regarding the new regulations. Com-
mittee Chair Gilbert Castillo informed 
the Board that the Committee had re-
ceived several requests for delays or 
waivers of the oral consultation require-
ment from affected pharmacies. He 
stated that the Committee's recommen-
dation was to proceed with implemen-
tation as scheduled. 
The Board then entertained testimony 
from representatives of several large 
pharmacy chains, HMOs, and trade as-
sociations, including Longs Drugs, Kai-
ser Permanente, and the California Re-
tailers Association. These companies 
complained that the imposition of such 
broad new duties on the entire industry 
may lead to selective compliance (de-
pending on the adequacy of the 
pharmacy's staffing), inconsistency, and 
potential liability problems. Further, and 
after eighteen months' lead time, these 
companies argued that they were un-
prepared to comply on January I with-
out the use of pharmacy technicians, 
and this new category of pharmacy em-
ployee is not expected to be authorized 
by regulations until at least April. The 
representatives also implied that if the 
regulations went into effect as sched-
uled, they may initiate litigation to chal-
lenge them. 
Board members pointed out that the 
effective date had already been delayed 
once in response to these concerns, and 
that it had been apparent for some time 
that the regulations providing for tech-
nicians would not be in place before the 
consultation requirement became effec-
tive. The Board voted 3-2 to proceed 
with implementation on January I. 
Notwithstanding that action, the 
Board continued to receive requests to 
once again delay implementation of the 
oral consultation requirement. Board 
President William Tan called a special 
meeting on December 4 to reconsider 
the Board's previous vote. At that meet-
ing, industry representatives again 
claimed to be unprepared to comply 
with the regulations without additional 
staff and expressed concern that deliv-
ery of medications might be delayed if 
the Board required them to comply 
with the oral consultation rule on Janu-
ary I. Finally, the Board voted to de-
lay the effective date until November 
I, 1992. 
Upon consultation with OAL, the 
Board will adopt a two-part procedure 
to accomplish the delay: (I) it will sus-
pend the regulations as an emergency 
action for the 120 days allowed for such 
actions under the Administrative Proce-
dure Act (Government Code section 
11346.l(e)); and(2) it will proceed with 
an ordinary rulemaking action to change 
the effective date to November I. The 
Board was scheduled to hold public 
hearings on the formal regulatory ac-
tion at its March 18 meeting; at this 
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writing, the emergency suspension 
awaits OAL approval. 
Partial Filling of Schedule II Pre-
scriptions. At its October 16 meeting, 
the Board held a public hearing on its 
proposed adoption of section 1745, Title 
16 of the CCR. As originally proposed, 
section 1745 would allow partial filling 
of Schedule II controlled substance pre-
scriptions for terminally ill patients who 
are in chronic pain, under certain cir-
cumstances. (See CRLR Vol. 11. No. 4 
(Fall 1991) p. I 05 for background in-
formation.) During the hearing, the 
Board amended the text to add new 
language which would also allow par-
tial filling when the prescription is for 
an inpatient of a skilled nursing facility. 
The Board released the modified lan-
guage for a 15-day comment period end-
ing on December 24, and was expected 
to adopt the new language at its January 
meeting. 
Federal Policy Guide Regarding 
New Drug Repacking. In a July 16 let-
ter to the federal Food and Drug Ad-
ministration (FDA), the Board sought 
clarification of FDA's Compliance 
Policy Guide 7 l 32c.06. (See CRLR Vol. 
11, No. 4 (Fall 1991) p. !04 for back-
ground information.) The guide defines 
FDA policy regarding drug manipula-
tions which are approved if conducted 
within the practice of pharmacy, and 
those manipulations which constitute 
"manufacturing" and require separate 
FDA approval. Although FDA has not 
formally replied to the Board, its dis-
trict supervisor for southern California 
forwarded a number of documents to 
the Board on this subject. The docu-
ments indicate that FDA is working on 
the issue with the National Association 
of Boards of Pharmacy (NABP). It is 
NABP's position that compounding and 
manufacturing are distinct activities, and 
that compounding is a proper part of the 
practice of pharmacy. Further, NABP 
opined that it is beyond the scope of 
FDA's authority for it to intrude "upon 
the state regulation of pharmacy prac-
tice." At its October meeting, the Board 
essentially agreed with NABP's posi-
tion, and noted that clarification is still 
needed as to whether the "breaking down 
of bulk drugs for prescription or known 
need" constitutes manufacturing. The 
Board voted to send another letter to 
FDA expressing its concern and seek-
ing such clarification. 
Part-Time Pharmacists-in-Charge. 
At its October meeting, the Board con-
tinued its discussion of possible amend-
ments to section 1709. I, Title 16 of the 
CCR, which governs the designation of 
the pharmacist-in-charge at each phar-
macy and prohibits a pharmacist from 
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acting as pharmacist-in-charge at more 
than one pharmacy. (See CRLR Vol. 11, 
No.4(Fall 199l)p.105forbackground 
information.) In response to inquiries, 
the Board decided to clarify one narrow 
exception to that prohibition. At the 
meeting, the Board agreed on a pro-
posed amendment that would allow a 
pharmacist to be pharmacist-in-charge 
at two pharmacies when each such phar-
macy employs only that pharmacist and 
is not open at any time when the other 
pharmacy for which that pharmacist is 
the pharmacist-in-charge is open. The 
Board anticipated publishing notice of 
this amendment in January and holding 
a public hearing at its March meeting. 
Regulatory Update. The following 
is a status update on regulatory changes 
considered and approved by the Board 
in recent months (see CRLR Vol. 11, 
No. 4 (Fall 1991) p. 105; Vol. 11, No. 3 
(Summer 1991) p. 102; and Vol. 11, No. 
2 (Spring 1991) p. 98 for background 
information): 
-Compounding for Office Use. The 
Board has adopted proposed new sec-
tion 1716.1, which defines the quantity 
of compounded medication which a 
pharmacist may furnish to a prescriber 
for office use under Business and Pro-
fessions Code section 4046(c)(l), and 
proposed new section 1716.2, which 
specifies the minimum types of records 
that pharmacies must keep when they 
furnish compounded medication to pre-
scribers in quantities larger than required 
for the prescriber's immediate office use 
or when a pharmacy compounds medi-
cation for future furnishing. At this writ-
ing, the proposed sections await review 
and approval by OAL. 
-Minimum Standards for Drug 
Wholesalers. At its May meeting, the 
Board adopted proposed amendments 
to section 1780, regarding minimum 
standards for drug wholesalers. At this 
writing, the proposed amendments await 
review and approval by OAL. 
LEGISLATION: 
AB 2070 (Isenberg), as amended 
August 19, would generally make it un-
lawful for specified healing arts licens-
ees to refer a person to any laboratory, 
pharmacy, clinic, or health care facility 
solely because the licensee has an own-
ership interest in the facility. However, 
a licensee could make those referrals if 
the person referred is the licensee's pa-
tient of record, there is no alternative 
provider or facility available, and the 
licensee certifies that to delay or forego 
the referral would cause an unneeded 
health risk to the patient. This two-year 
bill is pending in the Senate Rules 
Committee. 
SB 664 (Calderon) would prohibit 
pharmacists, among others, from charg-
ing, billing, or otherwise soliciting pay-
ment from any patient, client, customer, 
or third-party payor for any clinical labo-
ratory test or service if the test or ser-
vice was not actually rendered by that 
person or under his/her direct supervi-
sion, except as specified. This bill is 
pending in the Senate Business and Pro-
fessions Committee. 
AB 1226 (Hunter) would change 
the standard to be applied by the Di-
rector of the Department of Health Ser-
vices in establishing a formulary of ge-
neric drug types and drug products, to 
require him/her to identify those ge-
neric drug types and drug products 
which, if substituted by a pharmacist 
for a drug product described by the pre-
scriber by its trade or brand name, may 
pose a threat to the health and safety 
of patients. This bill is pending in the 
Assembly Health Committee. 
SB /033 (Marks) would permit phar-
macists to manufacture, measure, fit to 
the patient, sell, and repair medical de-
vices without regard to whether they 
bear a specified legend relating to a 
federal prohibition against dispensing 
without a prescription. This bill is pend-
ing in the Senate Business and Profes-
sions Committee. 
AB 855 (Hunter), as amended July 
16, would require a pharmacist to ob-
tain a patient's consent prior to filling a 
prescription order for a drug product 
prescribed by its trade or brand name 
with a substitute drug product. This two-
year bill is pending in the Senate Busi-
ness and Professions Committee. 
SB 917(Kopp), as amended June 11, 
would require certain health care ser-
vice plans that propose to offer a phar-
macy benefit or change its relationship 
with pharmacy providers to give writ-
ten or published notice to pharmacy ser-
vice providers of the plan's proposal, 
and give those providers an opportunity 
to submit a bid to participate in the 
plan's panel of providers on the terms 
proposed. This bill is pending at the 
Assembly desk. 
AB 8/9 (Speier). Existing law pro-
vides that it is not unlawful for pre-
scribed licensed health professionals to 
refer a person to a laboratory, pharmacy, 
clinic, or health care facility solely be-
cause the licensee has a proprietary in-
terest or co-ownership in the facility. 
This bill would instead provide that, 
subject to specified exceptions, it is un-
lawful for these licensed health profes-
sionals to refer a person to any labora-
tory, pharmacy, clinic, or health care 
facility which is owned in whole or in 
part by the licensee or in which the 
licensee has a proprietary interest; the 
bill would also provide that disclosure 
of the ownership or proprietary interest 
does not exempt the licensee from the 
prohibition. This bill is pending in the 
Assembly Health Committee. 
Future Legislation. At this writing, 
the Board is drafting three legislative 
proposals for the 1992 session. First, 
the Board may seek to repeal a portion 
of Business and Professions Code sec-
tion 4038 which exempts pharmacies 
and state-licensed drug manufacturers 
from licensure requirements as whole-
salers. The federal Prescription Drug 
Marketing Act requires state licensure 
of any firm that wholesales prescription 
drugs; thus, California's exemption is 
in conflict with the federal law. 
Second, the Board may seek to cor-
rect an erroneous reference in Business 
and Professions Code section 4033, 
which occurred as a result of sections 
being renumbered in 1980. 
Third, the Board may propose an 
amendment to Business and Professions 
Code section 4366 to allow the Board to 
recover its investigative and other en-
forcement costs from a disciplined lic-
ensee in cases other than drug diver-
sion, as is currently permitted. The Board 
wants broad discretion to recover its 
costs in other cases-e.g., filling unau-
thorized prescriptions or professional 
misconduct. 
The California Pharmacists' Asso-
ciation (CPA) has announced its four-
part legislative program for 1992. First, 
CPA will seek legislation aimed at out-
of-state mail order pharmacies. Accord-
ing to CPA, certain health care insurers 
and other plans currently encourage the 
use of out-of-state pharmacies by offer-
ing different co-payments or deductibles 
for drugs ordered from those pharma-
cies. CPA believes this system discrimi-
nates against California pharmacies and 
sends California dollars out-of-state, 
instead of supporting the local economy. 
CPA may seek legislation that would 
prohibit indemnity health care plans 
from providing unequal co-payment and 
deductible plans for out-of-state mail 
order pharmacy benefits. 
Second, CPA supports a pending con-
gressional resolution which would ask 
FDA to establish a transitional class of 
drugs between the existing prescription 
and over-the-counter classes. Included 
in this transitional category would be 
drugs that had been prescription-only, 
but are destined for reclassification by 
FDA as over-the-counter. Pharmacists 
would be allowed to dispense these 
drugs without a physician's authoriza-
tion, but would be required to consult 
with the patient on the use of the drug. 
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Third. CPA supports SB 917 (Kopp). 
a two-year bill which would require cer-
tain health care service plans. when of-
fering new pharmacy benefits in an area. 
to notify all pharmacies in the area and 
take bids from all such pharmacies (see 
supra). 
Finally. CPA may seek legislation to 
provide that it is a felony offense for 
any person who. in order to obtain any 
drug. falsely represents him/herself to 
be a physician or other person who may 
lawfully prescribe the drug. or falsely 
represents that he/she is acting on be-
half of a person who may lawfully pre-
scribe the drug, in a telephone commu-
;;ication with a registered pharmacist: 
currently. such an act constitutes a 
misdemeanor. 
RECENT MEETINGS: 
At its October 16 meeting, the Board 
once again discussed the possibility of 
adopting regulations to better control 
fee arrangements between physicians 
and home health agencies. (See CRLR 
Vol. 11, No. 4 (Fall 1991) p. 104: Vol. 
11, No. 3 (Summer 1991) p. IOI; and 
Vol. 11, No. 2 (Spring 1991) p. 97 for 
background information.) Specifically, 
the Board has been considering regula-
tions that would require the disclosure 
of contracts between home health care 
companies and health care consultants 
and which would provide the Board with 
authority to access the financial records 
of pharmacies. Department of Consumer 
Affairs (DCA) legal counsel Robert 
Miller suggested that the Board work 
with the DCA Director, who has broad 
investigory powers to obtain such 
records; the Board took no formal ac-
tion at the October meeting. 
Also at its October meeting, the 
Board discussed the final rule adopted 
by the federal Nuclear Regulatory Com-
mission (NRC) which requires medical 
licensees to establish quality manage-
ment programs in an effort to reduce 
misadministrations of radiopharma-
ceuticals. (See CRLR Vol. 11, No. 3 
(Summer 1991) p. IO I for background 
information.) The Board had previously 
opposed such a requirement as unnec-
essary in light of existing state regula-
tions, and not warranted by the data 
compiled by the NRC. Despite this and 
other opposition, the NRC adopted the 
rule. The Board heard testimony from 
radiopharmacists who believe the rule 
places an enormous burden on small 
businesses without adding any safety or 
other benefit to the public beyond what 
is already in place. The Board agreed 
to send another letter to the NRC re-
questing that the Commission recon-
sider the rule. 
The Board also discussed a letter 
from Deputy Attorney General Edward 
G. Weil advising the Board that the state 
Department of Justice has received nu-
merous complaints that pharmacists are 
not providing the FDA-required patient 
package insert (PPI) when dispensing 
conjugated estrogens. Mr. Weil recom-
mended that the Board notify its I icens-
ees of their potential liability not only 
under federal law. but for civil penaltie, 
under Proposition 65 when the PP! is 
not provided. Propo~ition 65. the Safe 
Drinking Water and Toxics Enforcement 
Act of 1986. provides that '"no person in 
the course of doing business sh al I know-
ingly and intentionally expose any indi-
vidual to a chemical known to the State 
of California to cause cancer. birth de-
fects or reproductive harm." without 
providing a ""clear and reasonable warn-
ing." Proposition 65 applies to comumer 
product~ in general, and to prescription 
drugs: in 1987. the state determined that 
conjugated estrogens are a chemical 
known to cause cancer under Proposi-
tion 65. The Board agreed to publish a 
warning to licensees in its next newslet-
ter. Board member Robert Toomajian 
noted that in light of the upcoming oral 
consultation requirement (see supra 
MAJOR PROJECTS), pharmac1'1s 
should be notified of other prescnption 
drugs that are known to cause cancer. 
Deputy Attorney General Bill Marcus 
opined that, to his knowledge, conJu-
gated estrogens are the only drug iden-
tified by the state as cancer-causing thus 
far in its Proposition 65 implementation 
process. 
FUTURE MEETINGS: 
May 27-28 in Sacramento. 
July 29-30 in San Francisco 
BOARD OF REGISTRATION FOR 
PROFESSIONAL ENGINEERS 
AND LAND SURVEYORS 
Executil·e Officer: Darlene Stroup 
(916) 920-7466 
The Board of Registration for Pro-
fessional Engineers and Land Survey-
ors (PELS) regulates the practice of en-
gineering and land surveying through 
its administration of the Professional 
Engineers Act, sections 6700 through 
6799 of the Business and Professions 
Code. and the Professional Land Sur-
veyors' Act, sections 8700 through 
8805 of the Business and Professions 
Code. The Board's regulations are 
found in Division 5, Title 16 of the 
California Code of Regulations (CCR). 
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The basic functions of the Board are 
to conduct examinations. issue certifi-
c,1tes, registrations. and/or licenses, and 
appropriately channel complaints 
against registrants/licensees. The Board 
1s add1t1onally empowered to suspend 
or revoke registrations/licenses. The 
Board considers the proposed deci~1ons 
of administrative law Judges who hear 
appeals of applicanb who are denied a 
registrat1on/1Icense, and those who have 
had their registration/license suspended 
or revoked for violations. 
The Board consists of thirteen mem-
bers: seven public members, one li-
censed land surveyor, four registered 
Practice Act engineers and one Title Act 
engineer. Eleven of the members are 
appointed by the Governor for four-
year terms which expire on a staggered 
basis. One public member 1s appointed 
by the Speaker of the Assembly and one 
by the Senate Rules Committee. 
The Board has established four stand-
ing committees and appoints other spe-
cial committees as needed. The four 
standing committees are Administration, 
Enforcement. Examination/Qualifica-
tions, and Legislation. The committees 
function in an advisory capacity unless 
specifically authorized to make binding 
decisions by the Board. 
Professional engineers are registered 
through the three Practice Act catego-
ries of civil, electrical, and mechanical 
engineering under section 6730 of the 
Business and Professions Code. The 
Title Act categories of agricultural. 
chemical, control system, corrosion, fire 
protection, industrial. manufacturing, 
metallurgical, nuclear, petroleum, qual-
ity, safety, and traffic engineering are 
registered under section 6732 of the 
Business and Professions Code. 
Structural engineering and geo-
techrncal engineering are authorities 
linked to the civil Practice Act and re-
quire an additional examination after 
qualification as a civil engineer. 
Board members and industry repre-
sentatives expressed sorrow at the Oc-
tober 12 death of Board member 
Clarence E. (Bill) Mackey. In Decem-
ber, Governor Wilson appointed David 
J. Slawson as the Board's land surveyor 
member. Slawson, the president of a 
civil engineering firm, replaces fo1mer 
Board member James Dorsey. The Gov-
ernor also appointed Mim Scott to the 
Board as a public member. Scott, a se-
nior vice-president of a master-planned 
community developer. fills the seat of 
former Board member Robert 
Thornberg. Finally, the Senate Rules 
Committee reappointed public member 
Sharon Reid to the Board for her final 
four-year term. 
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